Format
Sort by
Items per page

Send to

Choose Destination

Best matches for melanoma, acral OR melanoma:

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Buchbinder EI et al. Cancer. (2015)

Melanoma. Schadendorf D et al. Nat Rev Dis Primers. (2015)

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. Hodi FS et al. J Clin Oncol. (2013)

Search results

Items: 1 to 20 of 117379

1.

Malignant Melanoma: How Do We Meet the Needs of Young People and Their Families?

McInally W.

Compr Child Adolesc Nurs. 2018 Jan 19:1-4. doi: 10.1080/24694193.2018.1424418. [Epub ahead of print] No abstract available.

PMID:
29351502
2.

Unexpected impact of esterification on the antioxidant activity and (photo)stability of a eumelanin from 5,6-dihydroxyindole-2-carboxylic acid.

Micillo R, Iacomino M, Perfetti M, Panzella L, Koike K, D'Errico G, d'Ischia M, Napolitano A.

Pigment Cell Melanoma Res. 2018 Jan 19. doi: 10.1111/pcmr.12689. [Epub ahead of print]

PMID:
29350885
3.

Melanoma in situ mimicking a Lichen planus-like keratosis.

Sisti A, Fallaha A, Tassinari J, Nisi G, Grimaldi L, Eisendle K.

Acta Biomed. 2018 Jan 16;88(4):496-498. doi: 10.23750/abm.v88i4.5699.

PMID:
29350666
4.

Pediatric patients with cutaneous melanoma: A European study.

Brecht IB, De Paoli A, Bisogno G, Orbach D, Schneider DT, Leiter U, Offenmueller S, Cecchetto G, Godzinski J, Bien E, Stachowicz-Stencel T, Ben-Ami T, Chiaravalli S, Maurichi A, De Salvo GL, Sorbara S, Bodemer C, Garbe C, Reguerre Y, Ferrari A.

Pediatr Blood Cancer. 2018 Jan 19. doi: 10.1002/pbc.26974. [Epub ahead of print]

PMID:
29350487
5.

BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.

Chisholm JC, Suvada J, Dunkel IJ, Casanova M, Zhang W, Ritchie N, Choi Y, Park J, Das Thakur M, Simko S, Wan Rachel Tam N, Ferrari A.

Pediatr Blood Cancer. 2018 Jan 19. doi: 10.1002/pbc.26947. [Epub ahead of print]

PMID:
29350463
6.

miFAST: a novel and rapid microRNA target capture method.

Strong AMP, Berry SM, Beebe DJ, Li JL, Spiegelman VS.

Mol Carcinog. 2018 Jan 19. doi: 10.1002/mc.22780. [Epub ahead of print]

PMID:
29350431
7.

The burden of non-melanoma skin cancers in Auckland, New Zealand.

Pondicherry A, Martin R, Meredith I, Rolfe J, Emanuel P, Elwood M.

Australas J Dermatol. 2018 Jan 19. doi: 10.1111/ajd.12751. [Epub ahead of print]

PMID:
29350397
8.

Long non-coding RNA H19 promotes glucose metabolism and cell growth in malignant melanoma via miR-106a-5p/E2F3 axis.

Luan W, Zhou Z, Ni X, Xia Y, Wang J, Yan Y, Xu B.

J Cancer Res Clin Oncol. 2018 Jan 19. doi: 10.1007/s00432-018-2582-z. [Epub ahead of print]

PMID:
29350287
9.

Retrospective audit of patients referred for further treatment following Mohs surgery for non-melanoma skin cancer.

Wee E, Goh MS, Estall V, Tiong A, Webb A, Mitchell C, Murray W, Tran P, McCormack CJ, Henderson M, Hiscutt EL.

Australas J Dermatol. 2018 Jan 18. doi: 10.1111/ajd.12779. [Epub ahead of print]

PMID:
29349770
10.

Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress.

Stump TK, Aspinwall LG, Kohlmann W, Champine M, Hauglid J, Wu YP, Scott E, Cassidy P, Leachman SA.

J Genet Couns. 2018 Jan 19. doi: 10.1007/s10897-017-0185-5. [Epub ahead of print]

PMID:
29349527
11.

The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma.

Wan X, Liu R, Li Z.

Biomed Res Int. 2017;2017:5356737. doi: 10.1155/2017/5356737. Epub 2017 Nov 19.

PMID:
29349077
12.

The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis.

Vensby PH, Schmidt G, Kjær A, Fischer BM.

Am J Nucl Med Mol Imaging. 2017 Dec 20;7(6):255-262. eCollection 2017.

PMID:
29348980
13.

Inactivation/deficiency of DHODH induces cell cycle arrest and programed cell death in melanoma.

Liu L, Dong Z, Lei Q, Yang J, Hu H, Li Q, Ji Y, Guo L, Zhang Y, Liu Y, Cui H.

Oncotarget. 2017 Jul 19;8(68):112354-112370. doi: 10.18632/oncotarget.19379. eCollection 2017 Dec 22.

PMID:
29348830
14.

A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule.

Nollet M, Stalin J, Moyon A, Traboulsi W, Essaadi A, Robert S, Malissen N, Bachelier R, Daniel L, Foucault-Bertaud A, Gaudy-Marqueste C, Lacroix R, Leroyer AS, Guillet B, Bardin N, Dignat-George F, Blot-Chabaud M.

Oncotarget. 2017 Nov 28;8(68):112283-112296. doi: 10.18632/oncotarget.22736. eCollection 2017 Dec 22.

PMID:
29348825
15.

miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma.

Luo M, Wu L, Zhang K, Wang H, Zhang T, Gutierrez L, O'Connell D, Zhang P, Li Y, Gao T, Ren W, Yang Y.

Cell Death Differ. 2018 Jan 18. doi: 10.1038/s41418-017-0053-8. [Epub ahead of print]

PMID:
29348676
16.

Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles.

Pan J, Ruan W, Qin M, Long Y, Wan T, Yu K, Zhai Y, Wu C, Xu Y.

Sci Rep. 2018 Jan 18;8(1):1117. doi: 10.1038/s41598-018-19463-2.

PMID:
29348670
17.

Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.

Hosoi A, Takeda K, Nagaoka K, Iino T, Matsushita H, Ueha S, Aoki S, Matsushima K, Kubo M, Morikawa T, Kitaura K, Suzuki R, Kakimi K.

Sci Rep. 2018 Jan 18;8(1):1058. doi: 10.1038/s41598-018-19548-y.

PMID:
29348598
18.

Sensitizing tumor cells to conventional drugs: HSP70 chaperone inhibitors, their selection and application in cancer models.

Lazarev VF, Sverchinsky DV, Mikhaylova ER, Semenyuk PI, Komarova EY, Niskanen SA, Nikotina AD, Burakov AV, Kartsev VG, Guzhova IV, Margulis BA.

Cell Death Dis. 2018 Jan 18;9(2):41. doi: 10.1038/s41419-017-0160-y.

PMID:
29348557
19.

Dual suppression of inner and outer mitochondrial membrane functions augments apoptotic responses to oncogenic MAPK inhibition.

Serasinghe MN, Gelles JD, Li K, Zhao L, Abbate F, Syku M, Mohammed JN, Badal B, Rangel CA, Hoehn KL, Celebi JT, Chipuk JE.

Cell Death Dis. 2018 Jan 18;9(2):29. doi: 10.1038/s41419-017-0044-1.

PMID:
29348439
20.

<sup>18</sup>F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma.

Eschbach RS, Kazmierczak PM, Heimer MM, Todica A, Hirner-Eppeneder H, Schneider MJ, Keinrath G, Solyanik O, Olivier J, Kunz WG, Reiser MF, Bartenstein P, Ricke J, Cyran CC.

Cancer Imaging. 2018 Jan 18;18(1):2. doi: 10.1186/s40644-018-0135-y.

PMID:
29347968

Supplemental Content

Loading ...
Support Center